Optimizing the Prehospital Use of Stroke Systems of Care-Reacting to Changing Paradigms-Implementation (OPUS-i)
Launched by TEMPLE UNIVERSITY · Jul 26, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The OPUS-i trial is studying a new way to transport stroke patients in rural areas to hospitals more quickly and effectively. Researchers want to see if using a special transportation plan, based on data and evidence, can help patients get the care they need faster than the usual methods. This study will last for two years, but each participant will be involved for about three months.
To be eligible for this trial, participants must be 65 years or older and have a suspected stroke or transient ischemic attack (TIA) as recognized by emergency medical services (EMS). Unfortunately, people under 18 or those who are prisoners cannot take part in this study. If you or a loved one qualifies and chooses to participate, you can expect to be part of a group that aims to improve how quickly stroke patients receive treatment, which could lead to better health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical impression of stroke/TIA by EMS clinicians
- Exclusion Criteria:
- • Age \< 18 years
- • Prisoner
About Temple University
Temple University is a leading academic institution located in Philadelphia, Pennsylvania, renowned for its commitment to research and innovation in the health sciences. As a clinical trial sponsor, Temple University leverages its extensive resources, including a diverse pool of participants and cutting-edge facilities, to advance medical knowledge and improve patient care. The university's clinical research initiatives are driven by a multidisciplinary team of experts dedicated to conducting high-quality studies that address critical health issues and contribute to the development of novel therapies. Through its partnerships with local and global organizations, Temple University aims to enhance the translation of research findings into practical applications that benefit communities and advance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Derek Isenberg, MD
Principal Investigator
Lewis Katz School of Medicine at Temple University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported